MedTrace Logo

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

NCT06207175 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1260

Last updated 2024-01-23

No results posted yet for this study

Summary

This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female Participants Aged 18 to 45 Years

Conditions

  • Human Papillomavirus Infection

Interventions

BIOLOGICAL

Nonavalent HPV study vaccine

A 3-dose regimen administered at months 0, 2 and 6.

BIOLOGICAL

GARDASIL® 9

A 3-dose regimen administered at months 0, 2 and 6.

Sponsors & Collaborators

  • University of Muhammadiyah Malang Hospital

    collaborator UNKNOWN

  • Dr. M Djamil Hospital, Padang

    collaborator UNKNOWN

  • Beijing Health Guard Biotechnology, Inc

    lead INDUSTRY

Principal Investigators

  • Yu Hongyang · Beijing Health Guard Biotechnology, Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2024-11-17
Completion
2026-01-25

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06207175 on ClinicalTrials.gov